The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices

American Journal of Cardiovascular Drugs

Volumn 10, Issue 6, 2010, Pages 369-382

  Plans Rubi, Pedró ^a  

^a General Directorate of Public Health   (Spain)

Author keywords

Atorvastatin, therapeutic use; Colestyramine, therapeutic use; Cost effectiveness; Ezetimibe, therapeutic use; Fluvastatin, therapeutic use; Generic drugs; HMG CoA reductase inhibitors, therapeutic use; Hypercholesterolaemia, treatment; LDL cholesterol; Lovastatin, therapeutic use; Pravastatin, therapeutic use; Rosuvastatin, therapeutic use; Simvastatin, therapeutic use.

Indexed keywords

ATORVASTATIN; COLESTYRAMINE; EZETIMIBE; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; SPAIN; TREATMENT RESPONSE;

AZETIDINES; CHOLESTEROL, LDL; CHOLESTYRAMINE RESIN; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; HEALTH CARE COSTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SPAIN; TIME FACTORS;

EID: 78649371197     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11539150-000000000-00000     Document Type: Article

References (72)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel-III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP-III). JAMA 2001; 285: 2486-97
2. Plans-Rubio P. Cost-effectiveness of pharmacological therapies to reduce LDL-C levels. In: Pagano IS, Strait NB, editors. HDL and LDL cholesterol: physiology and clinical significance. New York (NY): Nova Biomedical Books, 2009
3. Hilleman DE, Phillips JO, Mohiuddin SM, et al. A population-based treat-totarget pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Clin Thera 1999; 21: 536-62
4. Tran YBL, Frial T, Miller PSJ. Statin's cost-effectiveness: a Canadian analysis of commonly used prescribed generic and brand name statins. Can J Clin Pharmacol 2007; 14: 205-14
5. Plans-Rubio P. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. Am J Cardiovascular Drugs 2006; 6: 177-88
6. Plans Rubio P. Impacto sobre elsistema sanitario catalan de laaplicaciondelas recomendaciones del segundo y tercer informes del National Cholesterol Education Program (ATP-II y ATP-III) sobre prevencion y control de la hipercolesterolemia en adultos. Clin Invest Arterioscl 2003; 15: 43-52
7. Ministerio de Sanidad y Consumo (Spain). Principios activos de mayor consumoen elSistema Nacionalde Salud durante 2007 Informacion Terapeutica del Sistema Nacional de Salud 2008; 32: 99-100
8. Ministerio de Sanidad y Consumo (Spain). Grupos terapeuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 2003. Informacion Terapeutica del Sistema Nacional de Salud 2004; 28: 121-4
9. Lopez-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000; 54: 87-123
10. Vademecum Internacional. Madrid: Medicom SA, 2010 COMB. Nomenclator, 2010. COMB, Barcelona, 2010
11. Garcia-Rodriguez LA, Lujan Masso-Gonzalez E, Wallander MA, et al. The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care. Pharmacol Drug Saf 2008; 17: 943-52
12. Harinder SM, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2007; 61: 1835-81
13. Haria M, NcTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997; 53: 299-336
14. Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs 1999; 57: 583-606 (Pubitemid 29196923)
15. Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80mg versus 10mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006; 97: 61-7
16. Henwood UM, Heel RC. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988; 36: 429-54
17. Higgins JPT, Thomson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. Br Med J 2009; 327: 557-60
18. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92: 152-60
19. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003; 326: 1423-9
20. Briggs A. Handling uncertainty in economic evaluations and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care. Oxford: Oxford University Press, 2001: 172-214
21. Johannesson M, Weinstein MC. On decision rules of cost-effectiveness analysis. J Health Econom 1993; 12:459-67
22. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 1991; 265: 1949-50
23. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New Engl J Med 2008; 358: 1431-43
24. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-60
25. Shepherd J, Cobe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7
26. Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther 1996; 18: 853-63
27. Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111: 185-91
28. Karalis DG, Ross AM, Vacari RM, et al. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002; 89: 667-71
29. Olsson AG, Eriksson M, Johnson O, et al., 3T Study Investigators. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Clin Ther 2003; 25: 119-38
30. Bakker-Arkema RG, Best J, Fayyad R, et al. A brief review paper ofthe efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis 1997; 131: 17-23
31. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1248-52
32. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25%to60%inpatients with primary hypercholesterolemiabyatorvastatin,anew HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-82
33. Branchi A, Fiorenza AM, Rovellini A, et al. Lowering effects of four different statins on serum triglyceride level. Eur J Clin Pharmacol 1999; 55: 499-502
34. Black DM, Bakker-Arkema R, Heinonen T, et al. Does the presence of either concurrent hypertensionor non-insulin-dependent diabetes mellitus affect the efficacy and safety of atorvastatin in patients with hypercholesterolemia? Am J Hypertens 1998; 11: 75-9
35. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16: 366-85
36. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993; 71: 1408-14
37. Farmer JA, Washington LC, Jones PH, et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther 1992; 14: 708-17
38. Jacotot B, Benghozi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol 1995; 76: 54A-6A
39. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44
40. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69
41. Jula A, Marniemi J, Huupponen R, et al. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002; 287: 598-605
42. Brown WV, Bays HE, Hassman DR, et al. Rosuvastatin Study Group: effectiveness and safety of rosuvastatin compared with pravastatin and simvas-tatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002; 144: 1036-43
43. Ose L, Davidson MH, Stein EA, et al. Lipid-altering efficacy and safety of simvastatin 80mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol 2000; 23: 39-46
44. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993; 71: 810-5
45. Banga JD, Jacotot B, Pfister P, et al. Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. French-Dutch Fluvastatin Study Group. Am J Med 1994; 96: 87S-93S
46. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9
47. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32: 140-6
48. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
49. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30
50. Prisant LM, Downton M, Watkins LO, et al. Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. Am J Cardiol 1996; 78: 420-4
51. Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 2002; 22: 89-99
52. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lip-oproteins and adverse event profile in 8245 patients with moderate hyper-cholesterolemia. Arch Intern Med 1991; 151: 43-9
53. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79: 1475-81
54. Rindone JP, Hiller D, Arriola G. A comparison of fluvastatin 40 mg every other day versus 20mg every day in patients with hypercholesterolemia. Pharmacotherapy 1998; 18: 836-9
55. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278-86
56. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001; 61: 1835-81
57. Zavoral JH, Haggerty BJ, Winick AG, et al. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial. Am J Cardiol 1995; 76: 37A-40A
58. Jacotot B, Banga JD, Waite R, et al. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multi-center study). French-Dutch Fluvastatin Study Group. Am J Cardiol 1995; 76 (Suppl.): 41A-46A
59. Peters TK, Muratti EN, Mehra M. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database. Am J Med 1994; 96: 79S-83S
60. Peters TK. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database. Am J Cardiol 1995; 76: 71A-5A
61. Serruys PW, Foley DP, Jackson G,et al.A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after succesful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1998; 20: 58-69
62. Blum CB. Comparison and properties of four inhibitors of 3-hydroxy-3-methylglutaril-coenzyme A reductase. Am J Cardiol 1994; 73: 3D-11D
63. Drazen JM, Jarcho JA, Morrissey S, et al. Cholesterol lowering and ezetimibe. New Engl J Med 2008; 358: 1507-8
64. Koren MJ, Smith DG, Hunninghake DB et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolemic patients: a comparison of atorvastatin, simvastatin, lovastatin and fluvasta-tin. Pharmacoeconomics 1998; 14: 59-70
65. MacLaine GDH, Patel H. A cost-effectiveness model of alternative statins to achieve target LDL-C levels. Int J Clin Pract 2001; 55: 243-9
66. Benner JS, Smith TW, Klingman D, et al. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health 2005; 8: 618-28
67. Gouveia Pinto C, Oliveira Carrageta M, Silva Miguel L. Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal. Value Health 2008; 11: 154-9
68. Zweifel P, Crivelli L. Price regulation of drugs: lessons from Germany. J Regulatory Economics 1996; 10: 257-73
69. Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy 1998; 44: 73-85
70. Puig-Junoy J. The impact of reference pricing interventions in the statin market. Health Policy 2007; 84: 14-29
71. Farmaindustria. El mercado del medicamento en Espana. Boletin de Coyuntura 2006; 11: 1-2
72. Higgins MJ, Graham SJH. Balancing innovation and access: patent challenges tip the scales. Science 2009; 326: 370-1